
About Innova Captab
Innova Captab is a publicly listed company based in Panchkula (India) founded in 2006 by Manoj Agarwal and Vinay Agarwal. Pharmaceutical formulations are manufactured by Innova Captab as a CDMO. The company has 782 employees. Innova Captab has completed 1 acquisition, including Sharon Bio. Its chief executive, as recorded, is Ajay Jain. Its Indian entity Innova Captab Limited reported revenue of βΉ1,637 Cr. Innova Captab offers products and services including CDMO Services, Domestic Branded Generics, and International Branded Generics. Its focus areas include Biopharma Outsourcing, Diversified and Small Molecules & Peptides.
Company details
Innova Captab is a CMO manufacturing pharmaceutical formulations in a variety of dosage forms. The company has 2 plants, out of which one is dedicated to the commercial manufacture of cephalosporin formulations in dosage forms such as tablets, capsules, dry syrups and dry injections, while the other is capable of manufacturing general tablet, capsule and ointment type formulations. The company claims that their facilities comply with the cGMP requirements of US FDA, UK MHRA, EU regulations, and, Schedule-M requirements of Indian Drugs and Cosmetics Act. Their clientele includes companies such as Abbott, Lupin and Wockhardt.
- Headquarters Panchkula, India
- Employees 782
- Founders Manoj Agarwal, Vinay Agarwal
- Stage Public
- SectorsHealthcare
- Emailβ’β’β’β’β’β’β’β’
- Phoneβ’β’β’β’ β’β’β’β’
- Website innovacaptab.com
- Social LinkedIn
- Legal Name Innova Captab Limited
- Market Cap₹5,938 Cr
INNOVACAP · NSE
- Share Price₹1,050.10
+1.19% today
- Revenue₹1,630 Cr
FY 2025-26 · +31.1% YoY
- EBITDA₹243 Cr
Margin 14.9%
- Net Profit₹140 Cr
FY 2025-26 · +9.3% YoY
- P/E (TTM)35.2x
P/B 5.0x
- ROE13.8%
ROCE 14.9%
- Debt / Equity0.33
Interest cover 8.6x
- Employee Count782
- Investments & Acquisitions
Associated legal entities of Innova Captab
Innova Captab is associated with 3 registered companies on The Company Check; the primary company is Innova Captab Limited, a listed company. Each company page carries the filings, financials, charges and directors of that entity.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2026) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Innova Captab Limited Listed CIN L24246MH2005PLC150371 | Active | 03 Jan 2005 | Thane, Maharashtra | ₹1,637 Cr | 1,246 | 10 | View details |
| Univentis Medicare Limited CIN U24232MH2015PLC402722 | Active | 03 Jul 2015 | Panvel, Maharashtra | ₹251 Cr | 341 | 5 | View details |
| Nugenic Pharma Private Limited CIN U24230HP2004PTC027717 | Active | 09 Dec 2004 | Baddi, Himachal Pradesh | ₹79.2 Cr | 232 | 4 | View details |
Products & Services of Innova Captab
Innova Captab offers a comprehensive portfolio of products and services, including CDMO Services, Domestic Branded Generics, and International Branded Generics.
Provides development and manufacturing for pharmaceutical companies.
Offers affordable branded generic medicines in India.
Supplies branded generics to global markets.
Board of directors of Innova Captab Limited (Innova Captab)
Innova Captab Limited is the primary company behind Innova Captab. The boards of the 3 registered companies of Innova Captab currently have 12 directors; the longest-serving is Manoj Kumar Lohariwala, appointed in 2004. 31 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Manoj Kumar Lohariwala DIN 00144656 | Director | 09 Dec 2004 | 21 yrs 11 mo | Nugenic Pharma Private Limited, Univentis Medicare Limited, Innova Captab Limited |
| Vinay Kumar Lohariwala DIN 00144700 | Director | 09 Dec 2004 | 21 yrs 11 mo | Nugenic Pharma Private Limited, Univentis Medicare Limited, Innova Captab Limited |
| Rohit Lohariwala DIN 06543263 | Director | 20 Mar 2014 | 12 yrs 7 mo | Nugenic Pharma Private Limited |
| Jayant Vasudeo Rao DIN 03627850 | Whole-time director | 22 Nov 2017 | 8 yrs 11 mo | Innova Captab Limited |
| Anup Agarwal DIN 05118963 | Director | 10 Jun 2020 | 6 yrs 5 mo | Univentis Medicare Limited |
| Rahul Luhariwala DIN 09345528 | Director | 21 Oct 2021 | 5 yrs | Nugenic Pharma Private Limited |
| Shirish Gundopant Belapure DIN 02219458 | Director | 01 Apr 2022 | 4 yrs 7 mo | Innova Captab Limited |
| Sudhir Kumar Bassi DIN 07819617 | Director | 01 Apr 2022 | 4 yrs 7 mo | Innova Captab Limited |
| Priyanka Dixit DIN 06578720 | Director | 01 Apr 2022 | 4 yrs 7 mo | Innova Captab Limited |
| Archit Aggarwal DIN 08127356 | Director | 01 Apr 2022 | 4 yrs 7 mo | Innova Captab Limited |
| Mahendar Korthiwada DIN 09558992 | Director | 28 Apr 2022 | 4 yrs 6 mo | Univentis Medicare Limited, Innova Captab Limited |
| Riteshe Paltani DIN 05316034 | Whole-time director | 19 May 2025 | 1 yr 6 mo | Univentis Medicare Limited |
People of Innova Captab
19 people are tracked at Innova Captab (9 in leadership, 10 in team); the tracked headcount is 782.
| Name | Role | Group |
|---|---|---|
Manoj Agarwal | Co-Founder & Managing Director | Leadership |
Vinay Agarwal | Co-Founder | Leadership |
Ajay Jain | CEO | Leadership |
Parveen Singh | Assistant General Manager Human Resources | Leadership |
| Managing Director | Leadership | |
Rishi Gupta | Group Chief Financial Officer | Leadership |
Himanshu Agarwal | General Manager International Business | Leadership |
Sujit Kumar Dana | Vice President & Head -r&d | Leadership |
Jatinder Singh | Head -drug Regulatory Affairs | Leadership |
Shivam Bansal | Finance Manager | Team |
Jitendra Kumar | Deputy Manager Quality Assurance | Team |
Mohit Sharma | Account Executive | Team |
Neha Khurpa | Sr. Executive DRA | Team |
Abhishek Sambyal | Senior Officer | Team |
Bhupinder Rana | HR Manager | Team |
Shyam Sharma | Jr. IPQA Officer At Innova Captab Ltd. | Team |
Shikha S. | QA Officer | Team |
Rajiv Kumar | Assistant Manager | Team |
Divya Sharma | Research Associate | Team |
Complete people profiles for Innova Captab
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Innova Captab
Innova Captab is a publicly listed company on the NSE with ticker symbol INNOVACAP in India, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date29 Dec 2023
- Listed onBSE: 544067 · NSE: INNOVACAP
- Listed entityInnova Captab Limited
- Exchange sectorHealth technology
- ISININE0DUT01020
- Share price₹1,053.40 (-1.08% on the day) · 2026-10-14
- Market capitalisation₹6,095 Cr
- Price to earnings38.6
- EPS (diluted, trailing year)₹27.31
- Dividend yield0.19%
- Volume (last session)39,790
Financials of Innova Captab
Exchange-reported figures of Innova Captab Limited, the listed company behind Innova Captab (NSE: INNOVACAP).
Financial Highlights
FY 2025-26 Β· ConsolidatedRevenue vs Net Profit ₹ Cr
Margin trends
Financial summary ₹ Cr
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 1,630 | 1,244 | 1,081 | 926 | 801 | 411 | 373 |
| Revenue growth | +31.1% | +15.0% | +16.7% | +15.7% | +94.9% | +10.0% | - |
| EBITDA | 243 | 186 | 154 | 114 | 96.02 | 54.48 | 50.93 |
| EBITDA margin | +14.9% | +15.0% | +14.3% | +12.3% | +12.0% | +13.3% | +13.6% |
| Profit before tax | 188 | 171 | 130 | 91.79 | 85.72 | 46.33 | 37.52 |
| Net profit | 140 | 128 | 94.32 | 66.28 | 63.96 | 34.37 | 27.87 |
| Net profit margin | +8.6% | +10.3% | +8.7% | +7.2% | +8.0% | +8.4% | +7.5% |
| EPS (βΉ) | 24.63 | 22.41 | 16.49 | 14.16 | 532.94 | 287.50 | 232.38 |
| Balance sheet | |||||||
| Total assets | 1,446 | 1,307 | 1,085 | 524 | 410 | 192 | 165 |
| Net worth | 1,091 | 959 | 831 | 323 | 209 | 145 | 110 |
| Total debt | 344 | 338 | 245 | 190 | 199 | 45.50 | 54.07 |
| Cash & bank | 3.87 | 68.17 | 86.75 | 18.88 | 2.44 | 11.89 | 5.18 |
| Net working capital | 515 | 436 | 349 | 266 | 216 | 94.45 | 92.77 |
| Cash flow | |||||||
| Cash from operations | 117 | 63.84 | 146 | 67.12 | 58.90 | 41.57 | 30.80 |
| Cash from investing | (107) | (152) | (499) | (90.84) | (188) | (19.67) | (6.04) |
| Cash from financing | (21.72) | 91.53 | 361 | 27.09 | 125 | (19.34) | (23.28) |
| Particulars | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 496 | 471 | 448 | 450 | 380 | 352 | 315 | 316 |
| Revenue growth (YoY) | +30.5% | +33.9% | +42.3% | +42.3% | +19.5% | +19.5% | - | - |
| Other income | 2.46 | 2.01 | 1.56 | 1.65 | 4.19 | 4.48 | 3.38 | 4.33 |
| EBITDA | 69.94 | 73.12 | 65.09 | 69.39 | 51.86 | 52.10 | 47.68 | 46.56 |
| EBITDA margin | +14.1% | +15.5% | +14.5% | +15.4% | +13.6% | +14.8% | +15.1% | +14.7% |
| Depreciation | 11.84 | 11.71 | 11.39 | 11.42 | 11.32 | 11.05 | 9.80 | 5.13 |
| Interest | 4.27 | 4.43 | 4.59 | 3.95 | 5.50 | 2.86 | 1.95 | 0.17 |
| Profit before tax | 56.29 | 58.99 | 50.67 | 55.67 | 39.23 | 42.67 | 39.31 | 45.59 |
| Tax | 13.87 | 14.86 | 12.59 | 13.53 | 9.57 | 11.67 | 9.74 | 11.39 |
| Net profit | 42.42 | 44.13 | 38.08 | 42.14 | 29.66 | 31.00 | 29.57 | 34.20 |
| EPS (βΉ) | 7.40 | 7.71 | 6.65 | 7.37 | 5.18 | 5.42 | 5.17 | 5.97 |
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 1,299 | 958 | 865 | 859 | 785 | 411 | 373 |
| Revenue growth | +35.6% | +10.8% | +0.7% | +9.3% | +91.3% | +10.0% | - |
| EBITDA | 151 | 122 | 108 | 98.52 | 98.51 | 54.48 | 50.93 |
| EBITDA margin | +11.7% | +12.8% | +12.5% | +11.5% | +12.5% | +13.3% | +13.6% |
| Profit before tax | 112 | 120 | 93.70 | 78.29 | 88.64 | 46.33 | 37.52 |
| Net profit | 83.67 | 89.52 | 69.55 | 55.88 | 66.19 | 34.37 | 27.87 |
| Net profit margin | +6.4% | +9.3% | +8.0% | +6.5% | +8.4% | +8.4% | +7.5% |
| EPS (βΉ) | 14.63 | 15.63 | 11.91 | 11.99 | 55.15 | 287.50 | 232.38 |
| Balance sheet | |||||||
| Total assets | 1,215 | 1,146 | 970 | 516 | 390 | 192 | 165 |
| Net worth | 887 | 813 | 724 | 315 | 211 | 145 | 110 |
| Total debt | 321 | 329 | 244 | 190 | 176 | 45.03 | 54.07 |
| Cash & bank | 1.99 | 67.89 | 86.35 | 14.99 | 2.19 | 11.89 | 5.18 |
| Net working capital | 400 | 323 | 258 | 220 | 160 | 94.34 | 92.77 |
| Cash flow | |||||||
| Cash from operations | 34.11 | 19.80 | 112 | 39.28 | 58.34 | 41.57 | 30.80 |
| Cash from investing | (14.06) | (99.75) | (472) | (87.53) | (188) | (19.67) | (6.04) |
| Cash from financing | (33.99) | 83.86 | 368 | 51.29 | 125 | (19.33) | (23.28) |
| Particulars | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 405 | 400 | 358 | 364 | 290 | 287 | 243 | 249 |
| Revenue growth (YoY) | +39.7% | +39.6% | +47.7% | +46.4% | +20.7% | +26.5% | - | - |
| Other income | 2.90 | 2.70 | 2.68 | 3.21 | 4.63 | 4.32 | 4.36 | 3.49 |
| Total expenses | 352 | 346 | 320 | 317 | 261 | 252 | 214 | 216 |
| EBITDA | 52.97 | 54.05 | 38.64 | 47.00 | 29.32 | 34.82 | 28.18 | 32.50 |
| EBITDA margin | +13.1% | +13.5% | +10.8% | +12.9% | +10.1% | +12.1% | +11.6% | +13.1% |
| Depreciation | 9.89 | 9.68 | 9.40 | 9.41 | 9.48 | 9.08 | 7.81 | 3.08 |
| Interest | 3.95 | 4.03 | 3.98 | 3.47 | 5.21 | 2.77 | 1.87 | 0.13 |
| Profit before tax | 42.03 | 43.04 | 27.94 | 37.33 | 19.26 | 27.29 | 22.86 | 32.78 |
| Tax | 10.05 | 10.97 | 6.78 | 9.43 | 4.93 | 7.00 | 5.73 | 8.37 |
Financial Statements
| Particulars | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 496 | 471 | 448 | 450 | 380 | 352 | 315 | 316 |
| Revenue growth (YoY) | +30.5% | +33.9% | +42.3% | +42.3% | +19.5% | +19.5% | - | - |
| Other income | 2.46 | 2.01 | 1.56 | 1.65 | 4.19 | 4.48 | 3.38 | 4.33 |
| EBITDA | 69.94 | 73.12 | 65.09 | 69.39 | 51.86 | 52.10 | 47.68 | 46.56 |
| EBITDA margin | +14.1% | +15.5% | +14.5% | +15.4% | +13.6% | +14.8% | +15.1% | +14.7% |
| Depreciation | 11.84 | 11.71 | 11.39 | 11.42 | 11.32 | 11.05 | 9.80 | 5.13 |
| Interest | 4.27 | 4.43 | 4.59 | 3.95 | 5.50 | 2.86 | 1.95 | 0.17 |
| Profit before tax | 56.29 | 58.99 | 50.67 | 55.67 | 39.23 | 42.67 | 39.31 | 45.59 |
| Tax | 13.87 | 14.86 | 12.59 | 13.53 | 9.57 | 11.67 | 9.74 | 11.39 |
| Net profit | 42.42 | 44.13 | 38.08 | 42.14 | 29.66 | 31.00 | 29.57 | 34.20 |
| EPS (βΉ) | 7.40 | 7.71 | 6.65 | 7.37 | 5.18 | 5.42 | 5.17 | 5.97 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 1,630 | 1,244 | 1,081 | 926 | 801 | 411 | 373 |
| Revenue growth | +31.1% | +15.0% | +16.7% | +15.7% | +94.9% | +10.0% | - |
| Other income | 7.42 | 12.05 | 12.49 | 9.20 | 2.88 | 1.37 | 1.30 |
| Total expenses | 1,387 | 1,058 | 927 | 813 | 705 | 356 | 322 |
| Employee cost | 167 | 117 | 90.66 | 54.80 | 40.46 | 22.33 | 20.24 |
| EBITDA | 243 | 186 | 154 | 114 | 96.02 | 54.48 | 50.93 |
| EBITDA margin | +14.9% | +15.0% | +14.3% | +12.3% | +12.0% | +13.3% | +13.6% |
| Depreciation | 45.18 | 24.78 | 15.96 | 11.08 | 7.50 | 5.59 | 10.08 |
| Interest | 16.90 | 2.41 | 21.46 | 19.97 | 5.68 | 3.93 | 4.63 |
| Profit before tax | 188 | 171 | 130 | 91.79 | 85.72 | 46.33 | 37.52 |
| Tax | 47.35 | 42.76 | 35.18 | 23.84 | 21.77 | 11.85 | 9.65 |
| Net profit | 140 | 128 | 94.32 | 66.28 | 63.96 | 34.37 | 27.87 |
| Net profit margin | +8.6% | +10.3% | +8.7% | +7.2% | +8.0% | +8.4% | +7.5% |
| EPS (βΉ) | 24.63 | 22.41 | 16.49 | 14.16 | 532.94 | 287.50 | 232.38 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 57.23 | 57.23 | 57.23 | 94.85 | 12.00 | 12.00 | 12.00 |
| Reserves & surplus | 1,034 | 902 | 774 | 229 | 197 | 133 | 98.35 |
| Shareholders' funds (net worth) | 1,091 | 959 | 831 | 323 | 209 | 145 | 110 |
| Minority interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Secured loans | 342 | 335 | 241 | 163 | 149 | 37.94 | 42.76 |
| Unsecured loans | 1.96 | 2.94 | 4.05 | 27.26 | 50.05 | 7.56 | 11.31 |
| Total debt | 344 | 338 | 245 | 190 | 199 | 45.50 | 54.07 |
| Total liabilities | 1,446 | 1,307 | 1,085 | 524 | 410 | 192 | 165 |
| Assets | |||||||
| Gross block | 956 | 901 | 406 | 216 | 205 | 107 | 94.26 |
| Net block | 842 | 830 | 358 | 183 | 183 | 79.14 | 73.16 |
| Capital work in progress | 15.50 | 22.52 | 341 | 21.54 | 0.03 | 7.26 | 0.00 |
| Investments | 41.29 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventories | 283 | 208 | 144 | 117 | 128 | 91.45 | 65.49 |
| Sundry debtors | 437 | 332 | 288 | 265 | 213 | 139 | 86.77 |
| Cash & bank balances | 3.87 | 68.17 | 86.75 | 18.88 | 2.44 | 11.89 | 5.18 |
| Loans & advances | 157 | 87.88 | 60.50 | 41.06 | 35.54 | 28.57 | 13.63 |
| Total current assets | 882 | 696 | 580 | 442 | 379 | 270 | 171 |
| Total current liabilities | 367 | 260 | 231 | 176 | 163 | 176 | 78.30 |
| Net working capital | 515 | 436 | 349 | 266 | 216 | 94.45 | 92.77 |
| Total assets | 1,446 | 1,307 | 1,085 | 524 | 410 | 192 | 165 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 15.52 | 11.73 | 3.53 | 0.15 | 4.80 | 2.24 | 0.75 |
| Net cash from operating activities | 117 | 63.84 | 146 | 67.12 | 58.90 | 41.57 | 30.80 |
| Net cash from investing activities | (107) | (152) | (499) | (90.84) | (188) | (19.67) | (6.04) |
| Net cash from financing activities | (21.72) | 91.53 | 361 | 27.09 | 125 | (19.34) | (23.28) |
| Net change in cash | (12.32) | 3.79 | 8.20 | 3.37 | (4.64) | 2.56 | 1.48 |
| Closing cash | 3.87 | 68.17 | 86.75 | 18.88 | 2.44 | 11.89 | 5.18 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | +31.1% | +15.0% | +16.7% | +15.7% | +94.9% | +10.0% | - |
| EBITDA growth | +30.5% | +20.5% | +35.9% | +18.4% | +76.3% | +7.0% | - |
| PBT growth | +10.1% | +32.0% | +41.1% | +7.1% | +85.0% | +23.5% | +51.6% |
| Net income growth | +9.3% | +36.1% | +42.3% | +3.6% | +86.1% | +23.3% | - |
| Revenue CAGR (3Y) | +20.7% | +15.8% | +38.1% | +35.4% | +31.0% | - | - |
| EBITDA CAGR (3Y) | +28.8% | +24.7% | +41.5% | +30.7% | +33.0% | - | - |
| Profitability & leverage | |||||||
| Net income margin | +8.6% | +10.3% | +8.7% | +7.3% | +8.0% | +8.4% | +7.5% |
| Return on capital employed | +14.9% | +14.5% | +18.8% | +23.9% | +30.4% | +28.2% | +26.3% |
| Return on net worth | +13.8% | +14.3% | +17.0% | +28.0% | +36.2% | +27.0% | +28.9% |
| Debt / equity | 0.33 | 0.33 | 0.38 | 0.73 | 0.69 | 0.39 | 0.65 |
| Long-term debt / equity | 0.22 | 0.25 | 0.26 | 0.29 | 0.21 | 0.07 | 0.20 |
| Interest cover | 8.55 | 1.49 | 15.50 | 19.47 | 6.42 | 8.04 | 11.33 |
| Efficiency & per share | |||||||
| Fixed asset turnover | 1.76 | 1.90 | 3.47 | 4.39 | 5.13 | 4.09 | 4.06 |
| Inventory turnover | 6.64 | 7.07 | 8.28 | 7.54 | 7.28 | 5.23 | 7.16 |
| Debtors turnover | 4.24 | 4.01 | 3.91 | 3.88 | 4.56 | 3.65 | 4.20 |
| EPS (βΉ) | 24.63 | 22.41 | 16.49 | 14.16 | 532.94 | 287.50 | 232.38 |
| Dividend per share (βΉ) | 2.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Book value per share (βΉ) | 190.61 | 167.66 | 145.20 | 57.61 | 1,738.38 | 1,206.84 | 919.62 |
| Particulars | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 405 | 400 | 358 | 364 | 290 | 287 | 243 | 249 |
| Revenue growth (YoY) | +39.7% | +39.6% | +47.7% | +46.4% | +20.7% | +26.5% | - | - |
| Other income | 2.90 | 2.70 | 2.68 | 3.21 | 4.63 | 4.32 | 4.36 | 3.49 |
| Total expenses | 352 | 346 | 320 | 317 | 261 | 252 | 214 | 216 |
| EBITDA | 52.97 | 54.05 | 38.64 | 47.00 | 29.32 | 34.82 | 28.18 | 32.50 |
| EBITDA margin | +13.1% | +13.5% | +10.8% | +12.9% | +10.1% | +12.1% | +11.6% | +13.1% |
| Depreciation | 9.89 | 9.68 | 9.40 | 9.41 | 9.48 | 9.08 | 7.81 | 3.08 |
| Interest | 3.95 | 4.03 | 3.98 | 3.47 | 5.21 | 2.77 | 1.87 | 0.13 |
| Profit before tax | 42.03 | 43.04 | 27.94 | 37.33 | 19.26 | 27.29 | 22.86 | 32.78 |
| Tax | 10.05 | 10.97 | 6.78 | 9.43 | 4.93 | 7.00 | 5.73 | 8.37 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 1,299 | 958 | 865 | 859 | 785 | 411 | 373 |
| Revenue growth | +35.6% | +10.8% | +0.7% | +9.3% | +91.3% | +10.0% | - |
| Other income | 13.24 | 16.78 | 10.72 | 8.73 | 2.86 | 1.37 | 1.30 |
| Total expenses | 1,147 | 836 | 757 | 760 | 687 | 356 | 322 |
| Employee cost | 111 | 62.74 | 50.11 | 43.60 | 36.30 | 22.22 | 20.24 |
| EBITDA | 151 | 122 | 108 | 98.52 | 98.51 | 54.48 | 50.93 |
| EBITDA margin | +11.7% | +12.8% | +12.5% | +11.5% | +12.5% | +13.3% | +13.6% |
| Depreciation | 37.37 | 17.02 | 11.40 | 10.66 | 7.40 | 5.59 | 10.08 |
| Interest | 15.42 | 2.17 | 13.59 | 18.30 | 5.33 | 3.93 | 4.63 |
| Profit before tax | 112 | 120 | 93.70 | 78.29 | 88.64 | 46.33 | 37.52 |
| Tax | 28.14 | 30.42 | 25.53 | 20.75 | 22.46 | 11.85 | 9.65 |
| Net profit | 83.67 | 89.52 | 69.55 | 55.88 | 66.19 | 34.37 | 27.87 |
| Net profit margin | +6.4% | +9.3% | +8.0% | +6.5% | +8.4% | +8.4% | +7.5% |
| EPS (βΉ) | 14.63 | 15.63 | 11.91 | 11.99 | 55.15 | 287.50 | 232.38 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 57.23 | 57.23 | 57.23 | 94.85 | 12.00 | 12.00 | 12.00 |
| Reserves & surplus | 829 | 756 | 666 | 220 | 199 | 133 | 98.35 |
| Shareholders' funds (net worth) | 887 | 813 | 724 | 315 | 211 | 145 | 110 |
| Secured loans | 319 | 326 | 240 | 163 | 139 | 37.94 | 42.76 |
| Unsecured loans | 1.95 | 2.91 | 3.86 | 27.07 | 36.99 | 7.09 | 11.31 |
| Total debt | 321 | 329 | 244 | 190 | 176 | 45.03 | 54.07 |
| Total liabilities | 1,215 | 1,146 | 970 | 516 | 390 | 192 | 165 |
| Assets | |||||||
| Gross block | 745 | 698 | 208 | 195 | 185 | 94.93 | 83.23 |
| Net block | 648 | 637 | 164 | 161 | 161 | 79.14 | 73.15 |
| Capital work in progress | 15.27 | 21.02 | 339 | 21.54 | 0.03 | 7.26 | 0.00 |
| Investments | 101 | 60.00 | 60.00 | 60.00 | 60.00 | 0.00 | 0.00 |
| Inventories | 204 | 140 | 93.99 | 97.27 | 105 | 91.45 | 65.49 |
| Sundry debtors | 330 | 249 | 217 | 230 | 174 | 139 | 86.77 |
| Cash & bank balances | 1.99 | 67.89 | 86.35 | 14.99 | 2.19 | 11.89 | 5.18 |
| Loans & advances | 172 | 72.37 | 39.70 | 36.45 | 31.95 | 28.57 | 13.63 |
| Total current assets | 709 | 529 | 437 | 378 | 313 | 270 | 171 |
| Total current liabilities | 309 | 206 | 180 | 158 | 153 | 176 | 78.30 |
| Net working capital | 400 | 323 | 258 | 220 | 160 | 94.34 | 92.77 |
| Total assets | 1,215 | 1,146 | 970 | 516 | 390 | 192 | 165 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 15.31 | 11.39 | 3.14 | 0.10 | 4.80 | 2.23 | 0.75 |
| Net cash from operating activities | 34.11 | 19.80 | 112 | 39.28 | 58.34 | 41.57 | 30.80 |
| Net cash from investing activities | (14.06) | (99.75) | (472) | (87.53) | (188) | (19.67) | (6.04) |
| Net cash from financing activities | (33.99) | 83.86 | 368 | 51.29 | 125 | (19.33) | (23.28) |
| Net change in cash | (13.94) | 3.92 | 8.25 | 3.03 | (4.69) | 2.56 | 1.48 |
| Closing cash | 1.99 | 67.89 | 86.35 | 14.99 | 2.19 | 11.89 | 5.18 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | +35.6% | +10.8% | +0.7% | +9.3% | +91.3% | +10.0% | - |
| EBITDA growth | +23.8% | +13.3% | +9.6% | +0.0% | +80.8% | +7.0% | - |
| PBT growth | -6.7% | +27.9% | +19.7% | -11.7% | +91.3% | +23.5% | +9997.0% |
| Net income growth | -6.5% | +28.7% | +24.5% | -15.6% | +92.6% | +23.3% | - |
| Revenue CAGR (3Y) | +14.8% | +6.9% | +28.2% | +32.0% | - | - | - |
| EBITDA CAGR (3Y) | +15.4% | +7.5% | +25.6% | +24.6% | - | - | - |
| Profitability & leverage | |||||||
| Net income margin | +6.4% | +9.3% | +7.9% | +6.7% | +8.4% | +8.4% | +7.5% |
| Return on capital employed | +10.8% | +11.5% | +14.4% | +21.3% | +32.3% | +28.2% | +25.5% |
| Return on net worth | +9.9% | +11.6% | +13.7% | +24.0% | +37.2% | +27.0% | +25.3% |
| Debt / equity | 0.38 | 0.37 | 0.42 | 0.70 | 0.62 | 0.39 | 0.49 |
| Long-term debt / equity | 0.27 | 0.30 | 0.29 | 0.30 | 0.21 | 0.07 | 0.11 |
| Interest cover | 13.53 | 2.06 | 14.07 | 20.83 | 5.85 | 8.04 | 11.33 |
| Efficiency & per share | |||||||
| Fixed asset turnover | 1.80 | 2.11 | 4.29 | 4.52 | 5.61 | 4.61 | 4.49 |
| Inventory turnover | 7.55 | 8.19 | 9.04 | 8.48 | 7.98 | 5.23 | 5.70 |
| Debtors turnover | 4.49 | 4.11 | 3.87 | 4.26 | 5.03 | 3.65 | 4.30 |
| EPS (βΉ) | 14.63 | 15.63 | 11.91 | 11.99 | 55.15 | 287.50 | 232.38 |
| Dividend per share (βΉ) | 2.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Book value per share (βΉ) | 154.94 | 142.06 | 126.47 | 55.90 | 175.69 | 1,206.84 | 919.62 |
Investments & Acquisitions by Innova Captab
Innova Captab has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Sharon Bio.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Manufacturer of pharmaceutical intermediates, actives, and finished dosages | sharonbio.com | Navi Mumbai, India | 1989 | Jun 2023 | β’β’β’β’ |
Complete acquisition details for Innova Captab
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Innova Captab
3 dated milestones of Innova Captab across 17 years, from founding to its latest funding, stage changes and deals.
- Founded Innova Captab is founded.
- Acquisition Acquires Sharon Bio.
- IPO Lists on the stock exchange (IPO).
Web traffic of Innova Captab
The website of Innova Captab (innovacaptab.com) receives about 2.7K visits a month.
- Monthly visits2.7K
▼ 22.4% vs previous month
Websites whose visitors overlap most with Innova Captab. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| hindustanfoodslimited.com | 100% | 11.9K | #1,697,428 | View details | |
| axiscapital.co.in | 82% | #717,797 | View details | ||
| tiindia.com | 49% | 24.6K | #1,268,205 | View details | |
| acmegenerics.in | 29% | 1.9K | #7,893,927 | View details | |
| swissgarnier.com | 29% | 1.1K | #13,288,880 | View details | |
| β’β’β’β’β’β’β’β’β’β’ | β’β’β’β’β’β’.com | β’β’% | β’.β’M | #β’β’β’β’β’ | β |
| β’β’β’β’β’β’β’β’β’β’ | β’β’β’β’β’β’.com | β’β’% | β’.β’M | #β’β’β’β’β’ | β |
| β’β’β’β’β’β’β’β’β’β’ | β’β’β’β’β’β’.com | β’β’% | β’.β’M | #β’β’β’β’β’ | β |
All 9 similar websites and full traffic analytics for Innova Captab
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 9 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Biopharma Outsourcing & Drug Delivery
3 companies that operate in the same segment as Innova Captab (Biopharma Outsourcing & Drug Delivery) in India, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of integrated contract research development and manufacturing services | 2007 | Bengaluru, Karnataka, India | USD 35.74 M | USD 226.38 M | 2,062 | |
Pharmaceutical and biotechnology company | 2005 | Hyderabad, Telangana, India | USD 229.73 M | USD 726.15 M | 548 | |
India's leading healthcare products distribution platform | 2018 | Mumbai, Maharashtra, India | USD 59.67 M | USD 702.49 M | 557 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Innova Captab
Complete news archive for Innova Captab
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Innova Captab
Innova Captab was founded in 2006.
Innova Captab is headquartered in Panchkula, India. It is registered at Panchkula, Haryana, India.
Ajay Jain is the CEO of Innova Captab, as recorded in our data.
Innova Captab has 782 employees.
The primary company behind Innova Captab, Innova Captab Limited, reported revenue of βΉ1,637 Cr for FY 2026, up 31% year on year.
Innova Captab is a CMO manufacturing pharmaceutical formulations in a variety of dosage forms. The company has 2 plants, out of which one is dedicated to the commercial manufacture of cephalosporin formulations in dosage forms such as tablets, capsules, dry syrups and dry injections, while the other is capable of manufacturing general tablet, capsule and ointment type formulations. The company claims that their facilities comply with the cGMP requirements of US FDA, UK MHRA, EU regulations, and, Schedule-M requirements of Indian Drugs and Cosmetics Act. Their clientele includes companies such as Abbott, Lupin and Wockhardt.
Innova Captab offers CDMO Services, Domestic Branded Generics, and International Branded Generics.
Yes, Innova Captab is publicly traded on NSE under the ticker symbol INNOVACAP.
Innova Captab has made 1 acquisition, including Sharon Bio.
Innova Captab is associated with 3 legal entities: Innova Captab Limited, Nugenic Pharma Private Limited, Univentis Medicare Limited.
The legal entities of Innova Captab currently have 15 directors, including Manoj Kumar Lohariwala, Vinay Kumar Lohariwala, Rohit Lohariwala and others.
